Underestimation of cardiovascular risk by the SCORE2 model in primary care: a call for recalibration - Top-Institutions - MDSpire

Underestimation of cardiovascular risk by the SCORE2 model in primary care: a call for recalibration

  • By

  • Vincent M I Voorbrood

  • Arthur M Bohnen

  • Angeline P Bosman

  • Peter R Rijnbeek

  • Dimitris Rizopoulos

  • Patrick J E Bindels

  • April 27, 2025

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    European Society of Cardiology (ESC)
    European Society of Cardiology (ESC)

    Sophia Antipolis, France

    Key Differentiators

    • Cardiology
    • Cardiovascular Epidemiology
    • Risk Prediction Modeling

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Cardiology
    • Epidemiology
    • Preventive Medicine

  • #3

    Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health

    Boston, MA

    Key Differentiators

    • Public Health
    • Cardiovascular Epidemiology
    • Biostatistics

  • #4

    University of Oxford, Nuffield Department of Population Health
    University of Oxford, Nuffield Department of Population Health

    Oxford, United Kingdom

    Key Differentiators

    • Population Health
    • Cardiovascular Epidemiology
    • Clinical Trials

  • #5

    Leiden University Medical Center (LUMC)
    Leiden University Medical Center (LUMC)

    Leiden, Netherlands

    Key Differentiators

    • Cardiology
    • Primary Care Research
    • Cardiovascular Epidemiology

Original Source(s)

Underestimation of cardiovascular risk by the SCORE2 model in primary care: a call for recalibration

  • by Vincent M I Voorbrood, Arthur M Bohnen, Angeline P Bosman, Peter R Rijnbeek, Dimitris Rizopoulos, Patrick J E Bindels

  • April 27, 2025

Related Content

Which Exercise Best Lowers Ambulatory BP?

‘Combined training and high-intensity interval training were also associated with reductions in 24-hour ambulatory blood pressure’

Infliximab as an Effective Second-Line Treatment for IVIG-Resistant Kawasaki Disease Accompanied by Severe Dyslipidemia

Retrospective cohort study assessing cardiovascular risk reduction through intensive blood pressure management in high-risk patients